Objective: To prepare Pingyangmycin gelatin microspheres (PYM-GMS) for carotid artery embolization therapy and to study the release characteristics in vivo and in vitro. Methods: PYM-GMS was prepared by optical doubl...Objective: To prepare Pingyangmycin gelatin microspheres (PYM-GMS) for carotid artery embolization therapy and to study the release characteristics in vivo and in vitro. Methods: PYM-GMS was prepared by optical double-phase emulsified condensation polymerization. Through UV-spectrophotometer drug content and encapsulation rate were measured. The characteristics of drug release in vitro which could simulate the actual state in vivo were tested by HPLC. Three ways of vein drop, artery perfusion and artery embolization were contrasted. Under the supervision of X-ray, PYM-GMS were perfused into the external carotid artery of rabbits by superselective artery embolization. Blood samples were tested at different time and analyzed statistically. Results: The roundness of PYM-GMS was 1.02?.005. The mean diameter was 85.6 mm, 78% of them ranging from 50-200 mm, which fitted the use of embolization. PYM content and encapsulation rate were 6.8% and 91.3% respectively. 70% of the drug was released in 3 h in the simulated environment in vivo and total drug was released after more than 6 h. After artery embolization with small dosage of PYM-GMS, the local drug concentration was 8 times higher than the blood drug concentration and the high level of local drug concentration was kept for more than 120 min. Conclusion: External carotid artery embolization with PYM-GMS, which significantly reduced the circulating drug level and employment dosage, could prolong the duration higher drug concentration and suit the purpose of targeted tumor therapy.展开更多
Manual Therapy is a rehabilitative approach based on the use of therapeutic procedures that includes several techniques, but this paper focuses on what is known as Positional Release (PR), a therapeutic model that inc...Manual Therapy is a rehabilitative approach based on the use of therapeutic procedures that includes several techniques, but this paper focuses on what is known as Positional Release (PR), a therapeutic model that includes a series of manoeuvres that are mainly used for the treatment of soft tissue. A deeper understanding of this type of therapeutic approach, especially its well known and widespread variant, Strain-Counterstrain, could, through controlled trials and systematic reviews, confirm its effectiveness, definitively explain the neurophysiological mechanism, and therefore make Positional Release another indispensable option in the professional expertise of the physiotherapist.展开更多
BACKGROUND Chimeric antigen receptor T-Cell(CAR-T)therapy is an effective new treatment for hematologic malignancies.Cytokine release syndrome(CRS)and neurologic toxicity are main toxicities.CRS-induced rhabdomyolysis...BACKGROUND Chimeric antigen receptor T-Cell(CAR-T)therapy is an effective new treatment for hematologic malignancies.Cytokine release syndrome(CRS)and neurologic toxicity are main toxicities.CRS-induced rhabdomyolysis(RM)followed by CART therapy treatment has not been previously reported.CASE SUMMARY We report a case of a 22-year-old woman with relapsed acute lymphoblastic leukemia obtained sequential cluster of differentiation(CD)19 and CD22 CAR-T infusion.This patient experienced grade 3 CRS with RM,mild hypotension requiring intravenous fluids,and mild hypoxia and was managed effectively with the IL-6 receptor antagonist tocilizumab.This patient had no signs of immune effector cell-associated neurologic syndrome.Restaging scans 30 d postCAR-T therapy demonstrated a complete remission,and the symptoms of muscle weakness improved through rehabilitation.CONCLUSION Myalgia is an easily overlooked symptom of severe CRS after CAR-T therapy.It is necessary to monitor myoglobin levels when a patient presents with symptoms of myalgia or acute renal insufficiency.展开更多
Boron neutron capture therapy(BNCT)is a novel binary therapy combining boron targeted drugs and neutron irradiation,which can selectively and effectively kill cancer cells at the cellular scale.Controlled release of b...Boron neutron capture therapy(BNCT)is a novel binary therapy combining boron targeted drugs and neutron irradiation,which can selectively and effectively kill cancer cells at the cellular scale.Controlled release of boron drug and its accumulation in tumor sites are the crux of BNCT.Here,we developed a^(10)B-boric acid(^(10)BA)-loaded nanofiber applying for BNCT by in situ administration.The nanofibers were obtained by electrospinning technique using polyethylene glycol/polylactide(PEO/PLA)block copolymers.By changing the ratio of hydrophilicity to hydrophobicity of the nanofibers,the controlled release and the effective accumulation of boron 10 isotope(^(10)B)were achieved in situ.The^(10)B content in tumor could reach to 2540μg/g,significantly exceeding the required level of 20–50μg/g for BNCT operation.Utilizing pertinent DNA damage experiments,direct evidence and quantified data of BNCT-induced DNA damage in tumor cells were obtained for the first time.Transcriptome sequencing was employed to predict the molecular mechanisms and potential signaling pathways of BNCT,providing theoretical basis for future combined therapies.The antitumor efficiency of BNCT was demonstrated by establishing mice model of subcutaneous tumor and tumor recurrence.The research presents a novel boron-loaded nanofiber mats for BNCT,which enables controlled drug release and holds significant potential in the treatment of unresectable or postoperative residual tumors.展开更多
Parenteral sustained release drug formulations, acting as preferable platforms for longterm exposure therapy, have been wildly used in clinical practice. However, most of these delivery systems must be given by hypode...Parenteral sustained release drug formulations, acting as preferable platforms for longterm exposure therapy, have been wildly used in clinical practice. However, most of these delivery systems must be given by hypodermic injection. Therefore, issues including needle-phobic, needle-stick injuries and inappropriate reuse of needles would hamper the further applications of these delivery platforms. Microneedles (MNs) as a potential alternative system for hypodermic needles can benefit from minimally invasive and self-administration. Recently, polymeric microneedle-mediated sustained release systems (MN@SRS) have opened up a new way for treatment of many diseases. Here, we reviewed the recent researches in MN@SRS for transdermal delivery, and summed up its typical design strategies and applications in various diseases therapy, particularly focusing on the applications in contraception, infection, cancer, diabetes, and subcutaneous disease. An overview of the present clinical translation difficulties and future outlook of MN@SRS was also provided.展开更多
Objective: The aim of our study was to probe into the effect of fluorouracil controlled release formulation in the local implant treatment of patients with advanced colorectal cancer. Methods: Sixty-four cases of pati...Objective: The aim of our study was to probe into the effect of fluorouracil controlled release formulation in the local implant treatment of patients with advanced colorectal cancer. Methods: Sixty-four cases of patients advanced colorectal cancer from August 2004 to February 2008 were selected for radical surgery, including 32 cases injected with intraoperative fluorouracil controlled release formulation in local implantation for 600 mg (the treatment group). Patients in another 32 cases received abdominal washing surgery by distilled water (the control group). All patients were followed up for 2 years and observed in aspects of the toxicity, 2-year survival rate, local recurrence rate and distant metastasis rate. Results: The 2-year survival rate and local recurrence rate in the treatment group was better than those in the control group (P < 0.05); as for toxicity and distant metastasis rate, no significant difference was observed. Conclusion: The effect of fluorouracil controlled release formulation in local implantation treatment was significant and the patient tolerance was satisfactory. Thus, it is an effective approach in the treatment of advanced colorectal cancer.展开更多
The aim of this paper was to evaluate controlled release behavior and the therapeutic efficacy of 5-FU-loaded Poly(lactic acid) (PLA)microspheres to human gastric cancer xenograft, and the targeting effect of VEGF/5-F...The aim of this paper was to evaluate controlled release behavior and the therapeutic efficacy of 5-FU-loaded Poly(lactic acid) (PLA)microspheres to human gastric cancer xenograft, and the targeting effect of VEGF/5-FU loaded PLA nanoparticles. 5-FU-loaded PLA microspheres were prepared by an emulsion evaporation method, and were characterized by scanning electron microscopy (SEM). 5-FU loaded PLA nanoparticles were characterized by (TEM), and particle size analyzer determined the distribution of nanoparticles size. The release performances of 5-FU microspheres in vitro were studied in PH 7.4 phosphate buffered saline. The therapeutic efficacy of 5-FU-loaded PLA microspheres in vivo were studied using MGC-803 (human stomach cancer) xenograft. 32 nude mice were divided into four groups (n =8), 5-FU loaded PLA microspheres were injected at tumor site. VEGF121 monoclonal antibody was connected with 5-FU loaded PLA nanoparticles through carbodimide. The targeted effect of VEGF 5-FU loaded nanoparticles in vivo were observed by single photon emission computed tomography (SPECT) after tail vein injection at 1 h and 2 h. SEM observation showed that microspheres were spherical, and the diameters of two kinds of microspheres were 1 μm and 5 μm respectively. The mean diameter of nanoparticles was 191.0 nm, and the index of polydispersity was 0.202. The drug was released following biphasic kinetics, initial burst and the following steady phase. 1 μm and 5 μm 5-FU-loaded microspheres both resulted in increased life span (1 μm microspheres median survival time=40.63 days, 5 μm microspheres median survival time=62.25 days), against 5-FU pure drug (median survival time=14.5 days). These results strongly suggest that 5-FU-loaded PLA microspheres increase life span of nude mice bearing MGC-803 tumors. After injection for 2 h, almost all the VEGF/5-FU loaded PLA nanoparticles could centralize at the human gastric cancer xenograft sites. That demonstrated VEGF monoclonal antibody remain its bioactivity after connection with nanoparticles, VEGF/5-FU loaded PLA nanoparticles had very exact targeting function for gastric tumor xenograft.展开更多
The combination of the first-line standard chemotherapeutic drug doxorubicin hydrochloride(DOX)and the molecular-targeted drug Herceptin(HCT)has emerged as a promising strategy for human epidermal growth receptor 2(HE...The combination of the first-line standard chemotherapeutic drug doxorubicin hydrochloride(DOX)and the molecular-targeted drug Herceptin(HCT)has emerged as a promising strategy for human epidermal growth receptor 2(HER-2)overexpressing breast cancer treatment.However,insufficient drug accumulation and severe cardiotoxicity are two major challenges that limit its clinical application.Herein,an in situ forming gold nanorods(AuNRs)-sodium alginate(ALG)hybrid hydrogel encapsulating DOX and HCT was engineered for tumor synergistic therapy involving injectable,dual-stimuli-responsive drug release,photothermal ablation,and drug-antibody synergistic therapy.The photothermal agent AuNRs,anticancer drug DOX,and anticancer antibody HCT were mixed in ALG solution,and after injection,the soluble ALG was quickly transformed into a hydrogel in the presence of Ca^(2+)in the body.Significantly,the hybrid hydrogel exhibits an extremely high photothermal conversion efficiency of 70%under 808 nm laser irradiation.The thermal effect can also provide photothermal stimulation to trigger the drug release from the gel matrix.In addition,the drug release rate and the releasing degree are also sensitive to the pH.In vitro studies demonstrated that the PEI-AuNR/DOX/HCT/ALG hydrogel has facilitated the therapeutic efficiency of each payload and demonstrated a strong synergistic killing effect on SK-BR-3 cells.In vivo imaging results showed that the local drug delivery system can effectively reduce the nonspecific distribution in normal tissues and increase drug concentration at tumor sites.The proposed hydrogel system shows significant clinical implications by easily introducing a sustainable photothermal therapy and a potential universal carrier for the local delivery of multiple drugs to overcome the challenges faced in HER-2 overexpressing cancer therapy.展开更多
目的探究食欲素A(Orexin-A)对女童中枢性性早熟的影响。方法选取2021年1月1日至2022年12月31日以来某妇幼保健院收治的特发性中枢性性早熟(idiopathic central precocious puberty,ICPP)女童30例为ICPP组,单纯性乳房发育女童30例为单纯...目的探究食欲素A(Orexin-A)对女童中枢性性早熟的影响。方法选取2021年1月1日至2022年12月31日以来某妇幼保健院收治的特发性中枢性性早熟(idiopathic central precocious puberty,ICPP)女童30例为ICPP组,单纯性乳房发育女童30例为单纯性乳房早发育(premature thelarche,PT)组,健康女童30例为对照组。收集患儿资料。对ICPP组患儿进行治疗并随访,检测患儿治疗前后血清Orexin-A水平。评价Orexin-A在ICCP诊断中的价值。结果ICPP组一般资料中身高、体重、骨龄、骨龄与年龄比值和阴毛发育评分,均高于PT组和对照组(P<0.05);3组患儿的血清学指标中,ICPP组的Orexin-A低于其他两组,E 2、LH、FSH、PRL显著高于PT组和对照组(P<0.05)。盆腔B超资料中,ICPP组的子宫容积、内膜厚度、卵巢容积、最大卵泡直径显著高于其他两组(P<0.05)。多因素分析显示,BMI、Orexin-A、子宫容积是女童ICPP的独立影响因素(P<0.05)。Orexin-A诊断ICPP的AUC为0.913,灵敏度为0.800,特异度为0.933。结论ICPP女童的身体和第二性征提前发育,E 2、LH、FSH和PRL激素水平上升,血清Orexin-A水平下降,卵巢和子宫发育提前,同时Orexin-A在诊断ICPP方面有良好的参考价值,具有较高的灵敏度和特异度,可以为性早熟筛查提供帮助。展开更多
基金This work was supported by the National Natural Science Foundation of China (No.30170271).
文摘Objective: To prepare Pingyangmycin gelatin microspheres (PYM-GMS) for carotid artery embolization therapy and to study the release characteristics in vivo and in vitro. Methods: PYM-GMS was prepared by optical double-phase emulsified condensation polymerization. Through UV-spectrophotometer drug content and encapsulation rate were measured. The characteristics of drug release in vitro which could simulate the actual state in vivo were tested by HPLC. Three ways of vein drop, artery perfusion and artery embolization were contrasted. Under the supervision of X-ray, PYM-GMS were perfused into the external carotid artery of rabbits by superselective artery embolization. Blood samples were tested at different time and analyzed statistically. Results: The roundness of PYM-GMS was 1.02?.005. The mean diameter was 85.6 mm, 78% of them ranging from 50-200 mm, which fitted the use of embolization. PYM content and encapsulation rate were 6.8% and 91.3% respectively. 70% of the drug was released in 3 h in the simulated environment in vivo and total drug was released after more than 6 h. After artery embolization with small dosage of PYM-GMS, the local drug concentration was 8 times higher than the blood drug concentration and the high level of local drug concentration was kept for more than 120 min. Conclusion: External carotid artery embolization with PYM-GMS, which significantly reduced the circulating drug level and employment dosage, could prolong the duration higher drug concentration and suit the purpose of targeted tumor therapy.
文摘Manual Therapy is a rehabilitative approach based on the use of therapeutic procedures that includes several techniques, but this paper focuses on what is known as Positional Release (PR), a therapeutic model that includes a series of manoeuvres that are mainly used for the treatment of soft tissue. A deeper understanding of this type of therapeutic approach, especially its well known and widespread variant, Strain-Counterstrain, could, through controlled trials and systematic reviews, confirm its effectiveness, definitively explain the neurophysiological mechanism, and therefore make Positional Release another indispensable option in the professional expertise of the physiotherapist.
文摘BACKGROUND Chimeric antigen receptor T-Cell(CAR-T)therapy is an effective new treatment for hematologic malignancies.Cytokine release syndrome(CRS)and neurologic toxicity are main toxicities.CRS-induced rhabdomyolysis(RM)followed by CART therapy treatment has not been previously reported.CASE SUMMARY We report a case of a 22-year-old woman with relapsed acute lymphoblastic leukemia obtained sequential cluster of differentiation(CD)19 and CD22 CAR-T infusion.This patient experienced grade 3 CRS with RM,mild hypotension requiring intravenous fluids,and mild hypoxia and was managed effectively with the IL-6 receptor antagonist tocilizumab.This patient had no signs of immune effector cell-associated neurologic syndrome.Restaging scans 30 d postCAR-T therapy demonstrated a complete remission,and the symptoms of muscle weakness improved through rehabilitation.CONCLUSION Myalgia is an easily overlooked symptom of severe CRS after CAR-T therapy.It is necessary to monitor myoglobin levels when a patient presents with symptoms of myalgia or acute renal insufficiency.
基金supported by the National Natural Science Foundation of China(Nos.21975246,52103193,and 52273124)the Natural Science Foundation of Shenzhen Municipality(No.JCYJ20230807112801003)+2 种基金the Projects of Jilin Province Science and Technology Development Plan(No.20220101052JC)the Fundamental Research Funds for the Central Universities(No.2412023QD017)the Fundamental Research Funds for the Central Universities-Excellent Youth Team Program(No.2412023YQ001).
文摘Boron neutron capture therapy(BNCT)is a novel binary therapy combining boron targeted drugs and neutron irradiation,which can selectively and effectively kill cancer cells at the cellular scale.Controlled release of boron drug and its accumulation in tumor sites are the crux of BNCT.Here,we developed a^(10)B-boric acid(^(10)BA)-loaded nanofiber applying for BNCT by in situ administration.The nanofibers were obtained by electrospinning technique using polyethylene glycol/polylactide(PEO/PLA)block copolymers.By changing the ratio of hydrophilicity to hydrophobicity of the nanofibers,the controlled release and the effective accumulation of boron 10 isotope(^(10)B)were achieved in situ.The^(10)B content in tumor could reach to 2540μg/g,significantly exceeding the required level of 20–50μg/g for BNCT operation.Utilizing pertinent DNA damage experiments,direct evidence and quantified data of BNCT-induced DNA damage in tumor cells were obtained for the first time.Transcriptome sequencing was employed to predict the molecular mechanisms and potential signaling pathways of BNCT,providing theoretical basis for future combined therapies.The antitumor efficiency of BNCT was demonstrated by establishing mice model of subcutaneous tumor and tumor recurrence.The research presents a novel boron-loaded nanofiber mats for BNCT,which enables controlled drug release and holds significant potential in the treatment of unresectable or postoperative residual tumors.
基金financial support from the National Natural Science Foundation of China (32071342 and 31922042)Guangdong Special Support Program (2019TQ05Y209)the Fundamental Research Funds for the Central Universities (19ykzd31)。
文摘Parenteral sustained release drug formulations, acting as preferable platforms for longterm exposure therapy, have been wildly used in clinical practice. However, most of these delivery systems must be given by hypodermic injection. Therefore, issues including needle-phobic, needle-stick injuries and inappropriate reuse of needles would hamper the further applications of these delivery platforms. Microneedles (MNs) as a potential alternative system for hypodermic needles can benefit from minimally invasive and self-administration. Recently, polymeric microneedle-mediated sustained release systems (MN@SRS) have opened up a new way for treatment of many diseases. Here, we reviewed the recent researches in MN@SRS for transdermal delivery, and summed up its typical design strategies and applications in various diseases therapy, particularly focusing on the applications in contraception, infection, cancer, diabetes, and subcutaneous disease. An overview of the present clinical translation difficulties and future outlook of MN@SRS was also provided.
文摘Objective: The aim of our study was to probe into the effect of fluorouracil controlled release formulation in the local implant treatment of patients with advanced colorectal cancer. Methods: Sixty-four cases of patients advanced colorectal cancer from August 2004 to February 2008 were selected for radical surgery, including 32 cases injected with intraoperative fluorouracil controlled release formulation in local implantation for 600 mg (the treatment group). Patients in another 32 cases received abdominal washing surgery by distilled water (the control group). All patients were followed up for 2 years and observed in aspects of the toxicity, 2-year survival rate, local recurrence rate and distant metastasis rate. Results: The 2-year survival rate and local recurrence rate in the treatment group was better than those in the control group (P < 0.05); as for toxicity and distant metastasis rate, no significant difference was observed. Conclusion: The effect of fluorouracil controlled release formulation in local implantation treatment was significant and the patient tolerance was satisfactory. Thus, it is an effective approach in the treatment of advanced colorectal cancer.
文摘The aim of this paper was to evaluate controlled release behavior and the therapeutic efficacy of 5-FU-loaded Poly(lactic acid) (PLA)microspheres to human gastric cancer xenograft, and the targeting effect of VEGF/5-FU loaded PLA nanoparticles. 5-FU-loaded PLA microspheres were prepared by an emulsion evaporation method, and were characterized by scanning electron microscopy (SEM). 5-FU loaded PLA nanoparticles were characterized by (TEM), and particle size analyzer determined the distribution of nanoparticles size. The release performances of 5-FU microspheres in vitro were studied in PH 7.4 phosphate buffered saline. The therapeutic efficacy of 5-FU-loaded PLA microspheres in vivo were studied using MGC-803 (human stomach cancer) xenograft. 32 nude mice were divided into four groups (n =8), 5-FU loaded PLA microspheres were injected at tumor site. VEGF121 monoclonal antibody was connected with 5-FU loaded PLA nanoparticles through carbodimide. The targeted effect of VEGF 5-FU loaded nanoparticles in vivo were observed by single photon emission computed tomography (SPECT) after tail vein injection at 1 h and 2 h. SEM observation showed that microspheres were spherical, and the diameters of two kinds of microspheres were 1 μm and 5 μm respectively. The mean diameter of nanoparticles was 191.0 nm, and the index of polydispersity was 0.202. The drug was released following biphasic kinetics, initial burst and the following steady phase. 1 μm and 5 μm 5-FU-loaded microspheres both resulted in increased life span (1 μm microspheres median survival time=40.63 days, 5 μm microspheres median survival time=62.25 days), against 5-FU pure drug (median survival time=14.5 days). These results strongly suggest that 5-FU-loaded PLA microspheres increase life span of nude mice bearing MGC-803 tumors. After injection for 2 h, almost all the VEGF/5-FU loaded PLA nanoparticles could centralize at the human gastric cancer xenograft sites. That demonstrated VEGF monoclonal antibody remain its bioactivity after connection with nanoparticles, VEGF/5-FU loaded PLA nanoparticles had very exact targeting function for gastric tumor xenograft.
基金support from the National Natural Science Foundation of China (Nos.52101287 and U1806219)the Shenzhen Fundamental Research Program (No.JCYJ20190807092803583)+1 种基金the Natural Science Foundation of Jiangsu Province (No.BK20190205)supported by the Special Funding in the Project of the Taishan Scholar Construction Engineering and the Program of Jinan Science and Technology Bureau (No.2020GXRC019)as well as New Material Demonstration Platform Construction Project from the Ministry of Industry and Information Technology (No.2020-370104-34-03-043952-01-11).
文摘The combination of the first-line standard chemotherapeutic drug doxorubicin hydrochloride(DOX)and the molecular-targeted drug Herceptin(HCT)has emerged as a promising strategy for human epidermal growth receptor 2(HER-2)overexpressing breast cancer treatment.However,insufficient drug accumulation and severe cardiotoxicity are two major challenges that limit its clinical application.Herein,an in situ forming gold nanorods(AuNRs)-sodium alginate(ALG)hybrid hydrogel encapsulating DOX and HCT was engineered for tumor synergistic therapy involving injectable,dual-stimuli-responsive drug release,photothermal ablation,and drug-antibody synergistic therapy.The photothermal agent AuNRs,anticancer drug DOX,and anticancer antibody HCT were mixed in ALG solution,and after injection,the soluble ALG was quickly transformed into a hydrogel in the presence of Ca^(2+)in the body.Significantly,the hybrid hydrogel exhibits an extremely high photothermal conversion efficiency of 70%under 808 nm laser irradiation.The thermal effect can also provide photothermal stimulation to trigger the drug release from the gel matrix.In addition,the drug release rate and the releasing degree are also sensitive to the pH.In vitro studies demonstrated that the PEI-AuNR/DOX/HCT/ALG hydrogel has facilitated the therapeutic efficiency of each payload and demonstrated a strong synergistic killing effect on SK-BR-3 cells.In vivo imaging results showed that the local drug delivery system can effectively reduce the nonspecific distribution in normal tissues and increase drug concentration at tumor sites.The proposed hydrogel system shows significant clinical implications by easily introducing a sustainable photothermal therapy and a potential universal carrier for the local delivery of multiple drugs to overcome the challenges faced in HER-2 overexpressing cancer therapy.
